US4783443A
(en)
|
1986-03-03 |
1988-11-08 |
The University Of Chicago |
Amino acyl cephalosporin derivatives
|
US5844092A
(en)
|
1994-03-18 |
1998-12-01 |
Genentech, Inc. |
Human TRK receptors and neurotrophic factor inhibitors
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US6677135B1
(en)
|
1996-05-08 |
2004-01-13 |
Biogen, Inc. |
Ret ligand (RetL) for stimulating neutral and renal growth
|
KR100587556B1
(ko)
|
1996-05-08 |
2006-06-08 |
바이오겐 아이덱 엠에이 인코포레이티드 |
신경 및 신장 증식을 자극하기 위한 RET리간드(RetL)
|
US6682921B1
(en)
|
1996-08-21 |
2004-01-27 |
New York University |
Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinases
|
US6531152B1
(en)
|
1998-09-30 |
2003-03-11 |
Dexcel Pharma Technologies Ltd. |
Immediate release gastrointestinal drug delivery system
|
AU7103900A
(en)
|
1999-09-01 |
2001-03-26 |
Biogen, Inc. |
Ret ligand 5 (retl5) compositions and uses thereof
|
FI20000403A0
(fi)
|
2000-02-22 |
2000-02-22 |
Hannu Sariola |
GDNF perhesukuisten yhdisteiden käyttö kivessyövän hoitoon tarkoitettujen tuotteiden valmistamiseksi
|
AU2001271422B2
(en)
|
2000-06-22 |
2005-12-22 |
Genentech, Inc. |
Agonist anti-trk-C monoclonal antibodies
|
WO2003020698A2
(en)
|
2001-09-06 |
2003-03-13 |
Prochon Biotech Ltd. |
Protein tyrosine kinase inhibitors
|
US7466344B2
(en)
|
2002-06-07 |
2008-12-16 |
Scimeasure Analytical Systems, Inc. |
High-speed low noise CCD controller
|
ITMI20021620A1
(it)
|
2002-07-23 |
2004-01-23 |
Novuspharma Spa |
Composto ad ativita' antitumorale
|
US20060116381A1
(en)
|
2002-07-24 |
2006-06-01 |
Fagin James A |
4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-ben-zamide for treating mutated-ret kinase associated diseases
|
ATE433447T1
(de)
|
2003-02-20 |
2009-06-15 |
Smithkline Beecham Corp |
Pyrimiidinverbindungen
|
JP2005106669A
(ja)
|
2003-09-30 |
2005-04-21 |
Olympus Corp |
生体関連物質の反応・測定システム
|
US20090143399A1
(en)
|
2003-10-14 |
2009-06-04 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Protein Kinase Inhibitors
|
CA2543116A1
(en)
|
2003-10-27 |
2005-05-19 |
Genelabs Technologies, Inc. |
Methods for preparing 7-(2'-substituted-.szlig.-d-ribofuranosyl)-4-(nr2r3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
|
MY141220A
(en)
|
2003-11-17 |
2010-03-31 |
Astrazeneca Ab |
Pyrazole derivatives as inhibitors of receptor tyrosine kinases
|
JP2007511575A
(ja)
|
2003-11-21 |
2007-05-10 |
ノバルティス アクチエンゲゼルシャフト |
タンパク質キナーゼ阻害剤としての1h−イミダゾキノリン誘導体
|
RU2006122853A
(ru)
|
2003-11-28 |
2008-01-10 |
Новартис АГ (CH) |
Производные диарилмочевины для лечения заболеваний, зависимых от протеинкиназы
|
SI1696920T1
(sl)
|
2003-12-19 |
2015-02-27 |
Plexxikon Inc. |
Spojine in postopki za razvoj modulatorjev ret
|
GB0330042D0
(en)
|
2003-12-24 |
2004-01-28 |
Pharmacia Italia Spa |
Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
|
GB0330043D0
(en)
|
2003-12-24 |
2004-01-28 |
Pharmacia Italia Spa |
Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
|
WO2005068424A1
(en)
|
2004-01-20 |
2005-07-28 |
Cell Therapeutics Europe S.R.L. |
Indolinone derivatives as receptor tyrosine kinase ihibitors
|
AR049769A1
(es)
|
2004-01-22 |
2006-09-06 |
Novartis Ag |
Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina
|
US20050222171A1
(en)
|
2004-01-22 |
2005-10-06 |
Guido Bold |
Organic compounds
|
WO2005099363A2
(en)
|
2004-03-26 |
2005-10-27 |
Whitehead Institute For Biomedical Research |
Methods of diagnosing, preventing and treating cancer metastasis
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
AR050365A1
(es)
|
2004-08-02 |
2006-10-18 |
Osi Pharm Inc |
Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos.
|
PE20060664A1
(es)
|
2004-09-15 |
2006-08-04 |
Novartis Ag |
Amidas biciclicas como inhibidores de cinasa
|
WO2006050076A1
(en)
|
2004-10-29 |
2006-05-11 |
Janssen Pharmaceutica, N.V. |
Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
|
DE102005003687A1
(de)
|
2005-01-26 |
2006-07-27 |
Sphingo Tec Gmbh |
Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
|
GB0501999D0
(en)
|
2005-02-01 |
2005-03-09 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
CN101257948A
(zh)
|
2005-02-18 |
2008-09-03 |
阿特努奥恩公司 |
嘧啶并二氮䓬衍生物及吲哚并蝶啶化合物
|
GB0507575D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
US7402579B2
(en)
|
2005-04-15 |
2008-07-22 |
Cylene Pharmaceuticals, Inc. |
Quinobenzoxazine analogs and compositions
|
MX2007014328A
(es)
|
2005-05-16 |
2008-02-12 |
Astrazeneca Ab |
Compuestos quimicos.
|
WO2006128042A2
(en)
|
2005-05-26 |
2006-11-30 |
The Johns Hopkins University |
Methods of identifying mutations in nucleic acid
|
CA2650999A1
(en)
|
2005-05-31 |
2006-12-07 |
The Pfahl Family Trust (Dated 9 July 1996) |
Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases
|
WO2006130673A1
(en)
|
2005-05-31 |
2006-12-07 |
Janssen Pharmaceutica, N.V. |
3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
|
ITRM20050290A1
(it)
|
2005-06-07 |
2006-12-08 |
Lay Line Genomics Spa |
Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
|
EP1893612B1
(en)
|
2005-06-22 |
2011-08-03 |
Plexxikon, Inc. |
Pyrrolo [2, 3-b]pyridine derivatives as protein kinase inhibitors
|
GB0515026D0
(en)
|
2005-07-21 |
2005-08-31 |
Novartis Ag |
Organic compounds
|
CA2620032C
(en)
|
2005-08-25 |
2014-02-04 |
Creabilis Therapeutics S.P.A. |
Polymer conjugates of k-252a and derivatives thereof
|
JP2009519218A
(ja)
|
2005-11-03 |
2009-05-14 |
エスジーエックス ファーマシューティカルズ、インコーポレイテッド |
ピリミジニル−チオフェンキナーゼモジュレータ
|
EP1785420A1
(en)
|
2005-11-14 |
2007-05-16 |
4Sc Ag |
Thiazole analogues and uses thereof
|
US20070149523A1
(en)
|
2005-11-14 |
2007-06-28 |
Jan Ehlert |
Thiazole Analogues and Uses Thereof
|
WO2007057399A2
(en)
|
2005-11-15 |
2007-05-24 |
Boehringer Ingelheim International Gmbh |
Treatment of cancer with indole derivatives
|
WO2007057397A1
(en)
|
2005-11-15 |
2007-05-24 |
Boehringer Ingelheim International Gmbh |
Treatment of cancer
|
GB0524436D0
(en)
|
2005-11-30 |
2006-01-11 |
Novartis Ag |
Organic compounds
|
AU2006322187A1
(en)
|
2005-12-08 |
2007-06-14 |
Novartis Ag |
Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors
|
WO2007077435A1
(en)
|
2005-12-30 |
2007-07-12 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
WO2007087245A2
(en)
|
2006-01-24 |
2007-08-02 |
Merck & Co., Inc. |
Ret tyrosine kinase inhibition
|
AU2007209689B2
(en)
|
2006-01-27 |
2012-03-15 |
Shanghai Hengrui Pharmaceutical Co. Ltd. |
Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors
|
CA2644356A1
(en)
|
2006-03-16 |
2007-09-27 |
Novartis Ag |
Heterocyclic organic compounds for the treatment of in particular melanoma
|
KR101549364B1
(ko)
|
2006-03-17 |
2015-09-01 |
암비트 바이오사이언시즈 코포레이션 |
질환 치료용 이미다졸로티아졸 화합물
|
KR101616388B1
(ko)
|
2006-03-27 |
2016-04-29 |
네르비아노 메디칼 사이언시스 에스.알.엘. |
키나제 억제제로서의 피리딜- 및 피리미디닐-치환된 피롤-, 티오펜- 및 푸란-유도체
|
BRPI0711628A2
(pt)
|
2006-05-15 |
2011-12-06 |
Irm Llc |
composto, composição farmacêutica, uso e processo para preparação do composto
|
WO2007136103A1
(ja)
|
2006-05-18 |
2007-11-29 |
Eisai R & D Management Co., Ltd. |
甲状腺癌に対する抗腫瘍剤
|
US8063225B2
(en)
|
2006-08-14 |
2011-11-22 |
Chembridge Corporation |
Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
|
WO2008031551A2
(en)
|
2006-09-12 |
2008-03-20 |
Novartis Forschungsstiftung, Zweigniederlassung |
Non-neuroendocrine cancer therapy
|
AU2007294686B2
(en)
|
2006-09-15 |
2013-10-31 |
Equinox Sciences, Llc |
Kinase inhibitor compounds
|
US20120225057A1
(en)
|
2006-10-11 |
2012-09-06 |
Deciphera Pharmaceuticals, Llc |
Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
|
EP1918291A1
(en)
|
2006-10-30 |
2008-05-07 |
Novartis AG |
3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators
|
EP3048099A3
(en)
|
2006-11-15 |
2016-09-21 |
YM BioSciences Australia Pty Ltd |
Inhibitors of kinase activity
|
EP2094701A2
(en)
|
2006-12-21 |
2009-09-02 |
Plexxikon, Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
WO2008079909A1
(en)
|
2006-12-21 |
2008-07-03 |
Plexxikon, Inc. |
Pyrrolo [2,3-b] pyridines as kinase modulators
|
PE20121126A1
(es)
|
2006-12-21 |
2012-08-24 |
Plexxikon Inc |
Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
|
US20080199426A1
(en)
|
2007-01-11 |
2008-08-21 |
Sukhatme Vikas P |
Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
|
JP2010516692A
(ja)
|
2007-01-19 |
2010-05-20 |
バイエル・ヘルスケア・エルエルシー |
化学療法剤に対し抵抗性を有する癌の処置
|
US20080234267A1
(en)
|
2007-03-20 |
2008-09-25 |
Karen Elizabeth Lackey |
Compounds and Methods of Treatment
|
US20110189167A1
(en)
|
2007-04-20 |
2011-08-04 |
Flynn Daniel L |
Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
|
WO2008137794A1
(en)
|
2007-05-04 |
2008-11-13 |
Irm Llc |
Compounds and compositions as c-kit and pdgfr kinase inhibitors
|
WO2008138184A1
(fr)
|
2007-05-14 |
2008-11-20 |
Shanghai Hengrui Pharmaceutical Co.Ltd. |
Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
|
US20090012045A1
(en)
|
2007-06-26 |
2009-01-08 |
Rigel Pharmaceuticals, Inc. |
Methods of Treating Cell Proliferative Disorders
|
WO2009007748A2
(en)
|
2007-07-09 |
2009-01-15 |
Astrazeneca Ab |
Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
|
WO2009012262A1
(en)
|
2007-07-16 |
2009-01-22 |
The Regents Of The University Of California |
Protein kinase modulating compounds and methods for making and using them
|
SG183036A1
(en)
|
2007-07-17 |
2012-08-30 |
Plexxikon Inc |
Compounds and methods for kinase modulation, and indications therefor
|
CA2693967A1
(en)
|
2007-07-19 |
2009-01-29 |
Schering Corporation |
Heterocyclic amide compounds as protein kinase inhibitors
|
NZ583450A
(en)
|
2007-07-20 |
2012-05-25 |
Nerviano Medical Sciences Srl |
Substituted indazole derivatives active as kinase inhibitors
|
WO2009017838A2
(en)
|
2007-08-01 |
2009-02-05 |
Exelixis, Inc. |
Combinations of jak-2 inhibitors and other agents
|
WO2009021137A2
(en)
|
2007-08-07 |
2009-02-12 |
Purdue Research Foundation |
Kinase inhibitors and uses thereof
|
EP2025678A1
(en)
|
2007-08-17 |
2009-02-18 |
Oncalis AG |
Pyrazolo[3,4-d]pyrimidine compounds and their use as modulators of protein kinase
|
WO2009042646A1
(en)
|
2007-09-24 |
2009-04-02 |
Curis, Inc. |
Anti-proliferative agents
|
CA2703329A1
(en)
|
2007-10-23 |
2009-04-30 |
Novartis Ag |
Use of trkb antibodies for the treatment of respiratory disorders
|
EP2215091B1
(en)
|
2007-12-04 |
2016-03-30 |
Nerviano Medical Sciences S.r.l. |
Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
|
CN101459004B
(zh)
|
2007-12-14 |
2011-02-09 |
深圳富泰宏精密工业有限公司 |
电子装置的按键面板结构及制造该按键面板结构的方法
|
EA028621B1
(ru)
|
2008-01-17 |
2017-12-29 |
Новартис Аг |
АНТИТЕЛО ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, КОТОРЫЙ СПЕЦИФИЧНО СВЯЗЫВАЕТ РЕЦЕПТОРНУЮ ТИРОЗИНКИНАЗУ (TrkB), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, И КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ УКАЗАННУЮ КОМПОЗИЦИЮ
|
JP2009203226A
(ja)
|
2008-01-31 |
2009-09-10 |
Eisai R & D Management Co Ltd |
ピリジン誘導体およびピリミジン誘導体を含有するレセプターチロシンキナーゼ阻害剤
|
TW200938542A
(en)
|
2008-02-01 |
2009-09-16 |
Irm Llc |
Compounds and compositions as kinase inhibitors
|
US20090209496A1
(en)
|
2008-02-15 |
2009-08-20 |
David Chaplin |
Methods and compositions for enhancing the efficacy of rtk inhibitors
|
US8822500B2
(en)
|
2008-03-19 |
2014-09-02 |
Chembridge Corporation |
Tyrosine kinase inhibitors
|
CA2718872C
(en)
|
2008-03-19 |
2016-09-13 |
Chembridge Corporation |
Novel tyrosine kinase inhibitors
|
EP2254886B1
(en)
|
2008-03-28 |
2016-05-25 |
Nerviano Medical Sciences S.r.l. |
3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
|
PE20091846A1
(es)
|
2008-05-19 |
2009-12-16 |
Plexxikon Inc |
DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
|
WO2009143018A2
(en)
|
2008-05-19 |
2009-11-26 |
Plexxikon, Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
CA2725185C
(en)
|
2008-05-23 |
2016-10-25 |
Novartis Ag |
Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
|
WO2009155052A1
(en)
*
|
2008-05-28 |
2009-12-23 |
Wyeth |
3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
|
CN104530052A
(zh)
|
2008-06-10 |
2015-04-22 |
普莱希科公司 |
用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症
|
WO2009155527A2
(en)
|
2008-06-19 |
2009-12-23 |
Progenics Pharmaceuticals, Inc. |
Phosphatidylinositol 3 kinase inhibitors
|
WO2010006432A1
(en)
|
2008-07-14 |
2010-01-21 |
Queen's University At Kingston |
Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
|
JP5677296B2
(ja)
|
2008-07-29 |
2015-02-25 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
グリオーマの治療のためのcdk阻害剤の使用
|
US8410685B2
(en)
|
2008-09-01 |
2013-04-02 |
Sharp Kabushiki Kaisha |
Organic electroluminescent panel, organic electroluminescent display, organic electroluminescent lighting device, and production methods thereof
|
WO2010028254A2
(en)
|
2008-09-05 |
2010-03-11 |
Auspek Pharmaceuticals, Inc. |
Substituted quinazoline inhibitors of growth factor receptor tyrosine kinases
|
EP2161271A1
(en)
|
2008-09-08 |
2010-03-10 |
Università Degli Studi Di Milano - Bicocca |
Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl
|
ES2536730T3
(es)
|
2008-09-19 |
2015-05-28 |
Nerviano Medical Sciences S.R.L. |
Derivados de 3,4-dihidro-2H-pirrolo[1,2-a]pirazin-1-ona
|
CA2738026C
(en)
|
2008-09-22 |
2017-01-24 |
Array Biopharma Inc. |
Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
|
CN102232071B
(zh)
|
2008-09-26 |
2016-03-23 |
财团法人卫生研究院 |
作为蛋白激酶抑制剂的稠合多环化合物
|
JP5600111B2
(ja)
|
2008-10-22 |
2014-10-01 |
アレイ バイオファーマ、インコーポレイテッド |
TRKキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピリミジン化合物
|
EP2358725A1
(en)
|
2008-11-06 |
2011-08-24 |
Ambit Biosciences Corporation |
Imidazolothiazole compounds as modulators of protein kinase
|
CN102223885B
(zh)
|
2008-11-24 |
2013-04-03 |
内尔维阿诺医学科学有限公司 |
用于治疗间皮瘤的cdk抑制剂
|
KR101061599B1
(ko)
|
2008-12-05 |
2011-09-02 |
한국과학기술연구원 |
비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
|
JO3265B1
(ar)
|
2008-12-09 |
2018-09-16 |
Novartis Ag |
مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
|
WO2010111527A1
(en)
|
2009-03-26 |
2010-09-30 |
Plexxikon, Inc. |
Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
|
TWI410418B
(zh)
|
2009-04-29 |
2013-10-01 |
Ind Tech Res Inst |
氮雜薁化合物、藥學組合物與抑制一細胞中蛋白質激酶之活性的方法
|
KR101614572B1
(ko)
|
2009-05-08 |
2016-04-21 |
아스테라스 세이야쿠 가부시키가이샤 |
디아미노 헤테로환 카르복사미드 화합물
|
US8765747B2
(en)
|
2009-06-12 |
2014-07-01 |
Dana-Farber Cancer Institute, Inc. |
Fused 2-aminothiazole compounds
|
EP3045457B1
(en)
|
2009-06-15 |
2018-05-09 |
Nerviano Medical Sciences S.r.l. |
Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
AU2010284254B2
(en)
|
2009-08-17 |
2015-09-17 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
KR101256018B1
(ko)
|
2009-08-20 |
2013-04-18 |
한국과학기술연구원 |
단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
|
FR2951172B1
(fr)
|
2009-10-13 |
2014-09-26 |
Pf Medicament |
Derives pyrazolopyridines en tant qu'agent anticancereux
|
KR101147550B1
(ko)
|
2009-10-22 |
2012-05-17 |
한국과학기술연구원 |
단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노[3,2-d]피리미딘 화합물
|
KR101116756B1
(ko)
|
2009-10-27 |
2012-03-13 |
한국과학기술연구원 |
단백질 키나아제 저해활성을 갖는 신규의 1,6-치환된 인돌 화합물
|
TR201802464T4
(tr)
|
2009-10-29 |
2018-03-21 |
Genosco |
Ki̇naz i̇nhi̇bi̇törleri̇
|
CA2780892C
(en)
|
2009-11-13 |
2017-02-14 |
Genosco |
Kinase inhibitors
|
KR101094446B1
(ko)
|
2009-11-19 |
2011-12-15 |
한국과학기술연구원 |
단백질 키나아제 저해활성을 가지는 2,4,7-치환된 티에노[3,2-d]피리미딘 화합물
|
EP2937345B1
(en)
|
2009-12-29 |
2018-03-21 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
AU2011210116B2
(en)
|
2010-01-29 |
2014-02-06 |
Catholic University Industry Academic Cooperation Foundation |
Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases
|
JP5883395B2
(ja)
|
2010-01-29 |
2016-03-15 |
ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ |
タンパク質キナーゼモジュレーターとしての6,7−ジヒドロイミダゾ[1,5−a]ピラジン−8(5h)−オン誘導体
|
KR101483215B1
(ko)
|
2010-01-29 |
2015-01-16 |
한미약품 주식회사 |
단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
|
EP2536414B1
(en)
|
2010-02-18 |
2016-07-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for preventing cancer metastasis
|
TWI619713B
(zh)
|
2010-04-21 |
2018-04-01 |
普雷辛肯公司 |
用於激酶調節的化合物和方法及其適應症
|
CA2800079C
(en)
|
2010-05-20 |
2020-09-15 |
Array Biopharma Inc. |
Macrocyclic compounds as trk kinase inhibitors
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
UY33597A
(es)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
WO2012047017A2
(ko)
|
2010-10-05 |
2012-04-12 |
크리스탈지노믹스(주) |
2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
|
JP2014005206A
(ja)
|
2010-10-22 |
2014-01-16 |
Astellas Pharma Inc |
アリールアミノヘテロ環カルボキサミド化合物
|
ES2602791T3
(es)
|
2011-01-26 |
2017-02-22 |
Nerviano Medical Sciences S.R.L. |
Derivados de pirrolo tricíclicos, proceso para su preparación y su uso como inhibidores de cinasa
|
US8916577B2
(en)
|
2011-01-26 |
2014-12-23 |
Nerviano Medical Sciences S.R.L. |
Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
|
CN102093421B
(zh)
|
2011-01-28 |
2014-07-02 |
北京康辰药业有限公司 |
一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
|
MA34948B1
(fr)
|
2011-02-07 |
2014-03-01 |
Plexxikon Inc |
Composes et procedes de modulation de kinase, et leurs indications
|
WO2012113774A1
(en)
|
2011-02-24 |
2012-08-30 |
Nerviano Medical Sciences S.R.L. |
Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors
|
EA201391230A1
(ru)
|
2011-02-25 |
2014-01-30 |
АйАрЭм ЭлЭлСи |
Соединения и композиции в качестве ингибиторов trk
|
US8791112B2
(en)
|
2011-03-30 |
2014-07-29 |
Arrien Pharmaceuticals Llc |
Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
|
ES2759615T3
(es)
|
2011-04-01 |
2020-05-11 |
Univ Utah Res Found |
Análogos de N-fenilpirimidina-2-amina sustituidos como inhibidores de la quinasa AXL
|
WO2012139930A1
(en)
|
2011-04-11 |
2012-10-18 |
Nerviano Medical Sciences S.R.L. |
Pyrazolyl-pyrimidine derivatives as kinase inhibitors
|
CN103502241B
(zh)
|
2011-04-19 |
2016-03-23 |
内尔维阿诺医学科学有限公司 |
作为激酶抑制剂的取代的嘧啶基-吡咯类活性剂
|
AR086042A1
(es)
*
|
2011-04-28 |
2013-11-13 |
Galapagos Nv |
Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
|
SI2707359T1
(sl)
|
2011-05-12 |
2017-02-28 |
Nerviano Medical Sciences S.R.L. |
Substituirani indazolni derivati, aktivni kot kinazni zaviralci
|
UA114711C2
(uk)
|
2011-05-13 |
2017-07-25 |
Еррей Біофарма Інк. |
Сполуки піролідинілсечовини й піролідинілтіосечовини як інгібітори кінази trka
|
RU2477723C2
(ru)
|
2011-06-16 |
2013-03-20 |
Общество С Ограниченной Ответственностью "Фьюжн Фарма" |
Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
|
CN102827073A
(zh)
*
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
WO2013016720A2
(en)
|
2011-07-28 |
2013-01-31 |
Gerinda Therapeutics, Inc. |
Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases
|
EP2736514B1
(en)
|
2011-07-28 |
2017-10-18 |
Nerviano Medical Sciences S.r.l. |
Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors
|
US9216172B2
(en)
|
2011-08-04 |
2015-12-22 |
National Cancer Center |
Method for determining effectiveness of cancer treatment by assessing the presence of a KIF5B-RET chimeric gene
|
AU2012298884B2
(en)
|
2011-08-23 |
2017-11-16 |
Foundation Medicine, Inc. |
Novel KIF5B-RET fusion molecules and uses thereof
|
MX370814B
(es)
|
2011-09-02 |
2020-01-08 |
Univ California |
Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
|
WO2013036232A2
(en)
|
2011-09-08 |
2013-03-14 |
Deciphera Pharmaceuticals, Llc |
Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
|
US8846712B2
(en)
*
|
2011-09-12 |
2014-09-30 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
WO2013042137A1
(en)
|
2011-09-19 |
2013-03-28 |
Aurigene Discovery Technologies Limited |
Bicyclic heterocycles as irak4 inhibitors
|
CN102408411B
(zh)
|
2011-09-19 |
2014-10-22 |
北京康辰药业股份有限公司 |
一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
|
EP2788350B1
(en)
|
2011-10-07 |
2017-12-06 |
Nerviano Medical Sciences S.r.l. |
4-ALKYL SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS
|
WO2013050446A1
(en)
|
2011-10-07 |
2013-04-11 |
Nerviano Medical Sciences S.R.L. |
SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS
|
BR112014011465A2
(pt)
|
2011-11-14 |
2017-05-09 |
Tesaro Inc |
modulação de determinadas quinases de tirosina
|
WO2013081188A1
(ja)
|
2011-11-30 |
2013-06-06 |
独立行政法人国立がん研究センター |
誘導悪性幹細胞
|
BR122019019582B1
(pt)
|
2011-12-30 |
2021-07-13 |
Hanmi Pharm. Co., Ltd. |
Compostos derivados de tieno[3,2-d]pirimidina, composição farmacêutica contendo os ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma doença causada por ativação anormal de uma proteína quinase
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
JP2015109806A
(ja)
|
2012-03-22 |
2015-06-18 |
アステラス製薬株式会社 |
新規ret融合体の検出法
|
TW201350479A
(zh)
|
2012-04-26 |
2013-12-16 |
Ono Pharmaceutical Co |
Trk阻害化合物
|
AU2013259267A1
(en)
|
2012-05-10 |
2014-11-06 |
Synta Pharmaceuticals Corp. |
Treating cancer with Hsp90 inhibitory compounds
|
CN106167485A
(zh)
|
2012-05-23 |
2016-11-30 |
内尔维阿诺医学科学有限公司 |
苯甲酰胺类,含有苯甲酰胺类的组合物以及苯甲酰胺类的制备方法
|
TWI585088B
(zh)
|
2012-06-04 |
2017-06-01 |
第一三共股份有限公司 |
作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物
|
DK2872491T3
(da)
|
2012-07-11 |
2021-08-09 |
Blueprint Medicines Corp |
Inhibitorer af fibroblastvækstfaktorreceptoren
|
WO2014017491A1
(ja)
|
2012-07-26 |
2014-01-30 |
独立行政法人国立がん研究センター |
Cep55遺伝子とret遺伝子との融合遺伝子
|
CN104507923B
(zh)
|
2012-08-02 |
2018-02-09 |
内尔维阿诺医学科学有限公司 |
作为激酶抑制剂的取代的吡咯类活性剂
|
WO2014039971A1
(en)
|
2012-09-07 |
2014-03-13 |
Exelixis, Inc. |
Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
|
AU2013321235B2
(en)
|
2012-09-25 |
2017-07-20 |
Chugai Seiyaku Kabushiki Kaisha |
RET inhibitor
|
US9604980B2
(en)
|
2012-11-07 |
2017-03-28 |
Nerviano Medical Sciences S.R.L. |
Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
|
WO2014075035A1
(en)
|
2012-11-12 |
2014-05-15 |
Cephalon, Inc. |
Bendamustine derivatives and methods of using same
|
EP3409670B1
(en)
|
2012-11-13 |
2020-09-09 |
Array Biopharma, Inc. |
N-pyrrolidinyl, n'-pyrazolyl- urea compounds as trka kinase inhibitors
|
WO2014078417A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
US9969694B2
(en)
|
2012-11-13 |
2018-05-15 |
Array Biopharma Inc. |
N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
US9828360B2
(en)
|
2012-11-13 |
2017-11-28 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
US9822118B2
(en)
|
2012-11-13 |
2017-11-21 |
Array Biopharma Inc. |
Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
WO2014078328A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
WO2014078322A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
WO2014078325A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
HUE031557T2
(en)
|
2012-11-13 |
2017-07-28 |
Array Biopharma Inc |
Bicyclic urea, thiourea, guanidine, and cyanoguadinine compounds used to treat pain
|
WO2014078372A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
IN2014MN02655A
(es)
|
2012-11-29 |
2015-08-21 |
Yeda Res & Dev |
|
WO2014086284A1
(zh)
|
2012-12-04 |
2014-06-12 |
上海医药集团股份有限公司 |
一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
|
DK2940014T3
(en)
|
2012-12-28 |
2018-12-10 |
Crystalgenomics Inc |
2,3-DIHYDRO-ISOINDOL-1-ON DERIVATIVE AS BTK KINase INHIBITORS AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
|
FR3000492B1
(fr)
|
2012-12-28 |
2015-09-11 |
Oribase Pharma |
Nouveaux derives azaindole en tant qu'inhibiteurs multikinases
|
FR3000494B1
(fr)
|
2012-12-28 |
2015-08-21 |
Oribase Pharma |
Nouveaux derives d'azaindoles en tant qu'inhibiteurs de proteines kinases
|
FR3000493A1
(fr)
|
2012-12-28 |
2014-07-04 |
Oribase Pharma |
Nouveaux inhibiteurs de proteines kinases
|
TW201443037A
(zh)
*
|
2013-01-09 |
2014-11-16 |
Gilead Sciences Inc |
治療用化合物
|
EP2960234B1
(en)
|
2013-02-19 |
2018-12-19 |
ONO Pharmaceutical Co., Ltd. |
Trk-inhibiting compound
|
WO2014160524A1
(en)
|
2013-03-14 |
2014-10-02 |
The Trustees Of The University Of Pennsylvania |
Cardio- metabolic and cascular effects of glp-1 metabolites
|
WO2014145485A2
(en)
*
|
2013-03-15 |
2014-09-18 |
The Trustees Of Columbia University In The City Of New York |
Map kinase modulators and uses thereof
|
WO2014160521A1
(en)
|
2013-03-15 |
2014-10-02 |
Blueprint Medicines Corporation |
Piperazine derivatives and their use as kit modulators
|
HUE033423T2
(en)
|
2013-03-15 |
2017-11-28 |
Glaxosmithkline Ip Dev Ltd |
Pyridine derivatives as rearrangement (RET) kinase inhibitors during transfection
|
US8937071B2
(en)
|
2013-03-15 |
2015-01-20 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds as rearranged during transfection (RET) inhibitors
|
WO2014184069A1
(en)
|
2013-05-14 |
2014-11-20 |
Nerviano Medical Sciences S.R.L. |
Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
|
EP3004060B1
(en)
|
2013-05-30 |
2019-11-27 |
Plexxikon Inc. |
Compounds for kinase modulation, and indications therefor
|
US10407509B2
(en)
|
2013-07-30 |
2019-09-10 |
Blueprint Medicines Corporation |
NTRK2 fusions
|
EP3027654B1
(en)
|
2013-07-30 |
2019-09-25 |
Blueprint Medicines Corporation |
Pik3c2g fusions
|
US20150057335A1
(en)
|
2013-08-20 |
2015-02-26 |
National Cancer Center |
Novel fusion genes identified in lung cancer
|
SG11201601341QA
(en)
|
2013-08-30 |
2016-03-30 |
Ambit Biosciences Corp |
Biaryl acetamide compounds and methods of use thereof
|
US9334263B2
(en)
|
2013-10-17 |
2016-05-10 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
ES2683127T3
(es)
|
2013-10-17 |
2018-09-25 |
Blueprint Medicines Corporation |
Composiciones útiles para tratar trastornos relacionados con la KIT
|
RU2704112C2
(ru)
|
2013-10-25 |
2019-10-24 |
Блюпринт Медсинс Корпорейшн |
Ингибиторы рецептора фактора роста фибробластов
|
GB201321146D0
(en)
|
2013-11-29 |
2014-01-15 |
Cancer Rec Tech Ltd |
Quinazoline compounds
|
WO2015082887A2
(en)
|
2013-12-02 |
2015-06-11 |
Bergenbio As |
Use of kinase inhibitors
|
US9695165B2
(en)
|
2014-01-15 |
2017-07-04 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
EP3636649B1
(en)
|
2014-01-24 |
2024-02-14 |
Turning Point Therapeutics, Inc. |
Diaryl macrocycles as modulators of protein kinases
|
CA3181899A1
(en)
|
2014-02-14 |
2015-08-20 |
Exelixis, Inc. |
Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
|
US10231965B2
(en)
|
2014-02-20 |
2019-03-19 |
Ignyta, Inc. |
Molecules for administration to ROS1 mutant cancer cells
|
EP3132054B1
(en)
|
2014-04-18 |
2021-06-30 |
Blueprint Medicines Corporation |
Met fusions
|
WO2015161274A1
(en)
|
2014-04-18 |
2015-10-22 |
Blueprint Medicines Corporation |
Pik3ca fusions
|
CN106459013B
(zh)
|
2014-05-15 |
2019-10-25 |
阵列生物制药公司 |
作为trka激酶抑制剂的化合物及其用途
|
US10246750B2
(en)
|
2014-06-10 |
2019-04-02 |
Blueprint Medicines Corporation |
Method for detection of a TECR:PKN1 or an ANXA4:PKN1 gene fusion
|
US10378063B2
(en)
|
2014-06-10 |
2019-08-13 |
Blueprint Medicines Corporation |
RAF1 fusions
|
WO2016011147A1
(en)
|
2014-07-17 |
2016-01-21 |
Blueprint Medicines Corporation |
Prkc fusions
|
EP3169804B3
(en)
|
2014-07-17 |
2019-09-18 |
Blueprint Medicines Corporation |
Fgr fusions
|
WO2016008433A1
(en)
|
2014-07-17 |
2016-01-21 |
Sunshine Lake Pharma Co., Ltd. |
Substituted urea derivatives and pharmaceutical uses thereof
|
WO2016011144A1
(en)
|
2014-07-17 |
2016-01-21 |
Blueprint Medicines Corporation |
Tert fusions
|
WO2016022569A1
(en)
|
2014-08-04 |
2016-02-11 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
ES2732026T3
(es)
|
2014-08-18 |
2019-11-20 |
Ono Pharmaceutical Co |
Sal de adición de ácido de un compuesto inhibidor de Trk
|
BR112017004673A2
(pt)
|
2014-09-08 |
2017-12-05 |
Glaxosmithkline Ip Dev Ltd |
formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida
|
PE20170677A1
(es)
|
2014-09-10 |
2017-05-13 |
Glaxosmithkline Ip Dev Ltd |
Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
|
EP3517526B1
(en)
|
2014-09-10 |
2020-08-19 |
GlaxoSmithKline Intellectual Property Development Limited |
Pyridinones as rearranged during transfection (ret) inhibitors
|
TWI538914B
(zh)
|
2014-10-03 |
2016-06-21 |
國立交通大學 |
蛋白質激酶之選擇性抑制劑、其醫藥組成物及其用途
|
CN107108631B
(zh)
|
2014-11-14 |
2020-06-16 |
内尔维阿诺医学科学有限公司 |
作为蛋白激酶抑制剂的6-氨基-7-二环-7-脱氮-嘌呤衍生物
|
KR102649887B1
(ko)
|
2014-11-16 |
2024-03-22 |
어레이 바이오파마 인크. |
(s)-n-(5-((r)-2-(2,5-디플루오로페닐)-피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복스아미드 히드로겐 술페이트의 결정질 형태
|
US20170356052A1
(en)
|
2014-11-18 |
2017-12-14 |
Blueprint Medicines Corporation |
Prkacb fusions
|
EP3233840B1
(en)
|
2014-12-16 |
2018-11-21 |
Eudendron S.r.l. |
Heterocyclic derivatives modulating activity of certain protein kinases
|
US10202365B2
(en)
|
2015-02-06 |
2019-02-12 |
Blueprint Medicines Corporation |
2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
|
KR101675984B1
(ko)
|
2015-02-23 |
2016-11-14 |
한양대학교 에리카산학협력단 |
티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물
|
AU2016226210A1
(en)
|
2015-03-03 |
2017-09-21 |
Caris Mpi, Inc. |
Molecular profiling for cancer
|
US10364247B2
(en)
|
2015-04-21 |
2019-07-30 |
Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine |
Preparation and use of novel protein kinase inhibitors
|
GB201512365D0
(en)
|
2015-07-15 |
2015-08-19 |
King S College London |
Novel therapy
|
MX2018000577A
(es)
|
2015-07-16 |
2018-09-05 |
Array Biopharma Inc |
Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la ret quinasa.
|
EP3120851A1
(en)
|
2015-07-21 |
2017-01-25 |
Pangaea Biotech S.L. |
4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
|
KR101766194B1
(ko)
|
2015-08-07 |
2017-08-10 |
한국과학기술연구원 |
RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물
|
WO2017027883A1
(en)
|
2015-08-13 |
2017-02-16 |
San Diego State University Research Foundation |
Atropisomerism for increased kinase inhibitor selectivity
|
MA41559A
(fr)
|
2015-09-08 |
2017-12-26 |
Taiho Pharmaceutical Co Ltd |
Composé de pyrimidine condensé ou un sel de celui-ci
|
WO2017049462A1
(zh)
|
2015-09-22 |
2017-03-30 |
合肥中科普瑞昇生物医药科技有限公司 |
一类新型的flt3激酶抑制剂及其用途
|
CN105255927B
(zh)
|
2015-09-30 |
2018-07-27 |
温州医科大学附属第一医院 |
一种kiaa1217-ret融合基因
|
EP4331585A3
(en)
|
2015-11-02 |
2024-05-15 |
Blueprint Medicines Corporation |
Inhibitors of ret
|
US20190002988A1
(en)
|
2015-12-08 |
2019-01-03 |
Boehringer Ingelheim International Gmbh |
Method of using a ret fusion gene as a biomarker to select non small cell lung cancer (nsclc) and thyroid cancer patients for a cancer treatment
|
WO2017122815A1
(ja)
|
2016-01-15 |
2017-07-20 |
公益財団法人がん研究会 |
新規融合体及びその検出法
|
TWI620748B
(zh)
|
2016-02-05 |
2018-04-11 |
National Health Research Institutes |
氨基噻唑化合物及其用途
|
WO2017145050A1
(en)
|
2016-02-23 |
2017-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
|
MD3269370T2
(ro)
|
2016-02-23 |
2020-05-31 |
Taiho Pharmaceutical Co Ltd |
Compus pirimidinic condensat nou sau sare a acestuia
|
WO2017161269A1
(en)
|
2016-03-17 |
2017-09-21 |
Blueprint Medicines Corporation |
Inhibitors of ret receptor tyrosine kinases
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
PL3442980T3
(pl)
|
2016-04-15 |
2021-12-06 |
Cancer Research Technology Limited |
Związki heterocykliczne jako inhibitory kinazy ret
|
EP3442535B1
(en)
*
|
2016-04-15 |
2022-06-01 |
Cancer Research Technology Limited |
Heterocyclic compounds as ret kinase inhibitors
|
TWI704148B
(zh)
*
|
2016-10-10 |
2020-09-11 |
美商亞雷生物製藥股份有限公司 |
作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
JOP20190077A1
(ar)
|
2016-10-10 |
2019-04-09 |
Array Biopharma Inc |
مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
|